Imaging for early stage breast cancer

Compelling associations in radiogenomics

Author, publication year

Study type, N

SNP

Gene

Cancer site, normal tissue endpoint(s)

Effect size

P value

Candidate gene, 2036 Candidate gene, 2636 Candidate gene, 5456

Rs1800629 SNP near TNFα

Breast, overall late toxicity Breast, overall late toxicity Breast and prostate, various endpoints Prostate, erectile dysfunction

OR 2.45

0.003

Talbot, 2012

XRCC1

Rs2682585

OR 0.77

0.02

Seibold , 2015

ATM

Rs1801516

OR ≈ 1.2 - 1.5 0.0001

Andreassen, 2016

5.46 x 10 -8

FSHRH

GWAS,79

Rs2268363

OR 7.03

Kerns, 2010

5.40 x 10 -8

GWAS, 1149 rs7120482 rs17630638

Intergenic

Prostate, rectal bleeding OR 3.1 - 6.7

Kerns, 2013

1.05 x 10 -12

KCND3

GWAS, 2011 rs2788612

Prostate, rectal incontinence

RR 9.91

Barnett, 2014

4.46 x 10 -11

TANC1

GWAS, 1742 Rs264663

Prostate, overall late toxicity

Per allele OR ≈ 6 OR 3.2 OR 2.7 Beta 0.3 OR 2.27

Fachal, 2014

4.16 x 10 -8 3.21 x 10 -8 6.27 x 10 -10 4.39 x 10 -8

Kerns, 2016

GWAS, 1564

Prostate, various endpoints

rs17599026 rs7720298 Rs11230328

Intergenic

Schack, 2018 Abstract OC-0485 ESTRO 37

GWAS, 1140

Intergenic

Head and neck, mucositis

rs28419191

Criteria : Candidate gene study : P-value below 0.05 in a study with several independent cohorts with total size >1,000 patients. GWAS: P-value below 5 x 10 -8 Modified from Andreassen CN et al., Cancer Letters 2016